<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04754945</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00001440</org_study_id>
    <secondary_id>NCI-2020-06548</secondary_id>
    <secondary_id>Winship5086-20</secondary_id>
    <secondary_id>P30CA138292</secondary_id>
    <nct_id>NCT04754945</nct_id>
  </id_info>
  <brief_title>Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis</brief_title>
  <official_title>Slow-Go Strategy for High Risk AL Amyloidosis: Isatuximab for Upfront Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects of isatuximab and to see how well it works in&#xD;
      treating patients with high risk immunoglobulin light chain amyloidosis (AL amyloidosis).&#xD;
      Isatuximab is a monoclonal antibody that may interfere with the ability of tumor cells to&#xD;
      grow and spread.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
        1. Test the safety and feasibility of isatuximab-based drug treatment.&#xD;
&#xD;
        2. Evaluate the preliminary efficacy of a slow-go approach in high risk AL amyloid&#xD;
           patients.&#xD;
&#xD;
      STUDY TREATMENT&#xD;
&#xD;
      Each patient starts by receiving increasing intensity of treatment for AL Amyloidosis up to&#xD;
      maximum tolerance, and then maintenance Isatuximab thereafter for a specified period.&#xD;
&#xD;
      All patients will receive Isatuximab (weekly x 4 then every other week) plus dexamethasone 4&#xD;
      mg PO/IV days weekly. If tolerating Isatuximab/Dex4 (earliest time to escalate C1D15), add&#xD;
      Velcade to 1 mg/m2 SQ weekly. If tolerating Isa/Vel1.0/Dex4 (earliest time to escalate C2D1),&#xD;
      increase dexamethasone to 12 mg weekly. If tolerating Isa/Velcade1.0/Dex12 (earliest time to&#xD;
      escalate C3D1), increase Velcade to 1.3 mg/m2 SQ. If tolerating Isa/Velcade1.3/Dex12&#xD;
      (earliest time to escalate C4D1), add cyclophosphamide 300 mg IV weekly. If tolerating&#xD;
      Isa/Velcade1.3/Cy300/Dex12 (earliest time to escalate C5D1), increase cyclophosphamide to 400&#xD;
      mg IV weekly. If tolerating Isa/Velcade1.3/Cy400/Dex12 (earliest time to escalate C6D1),&#xD;
      increase cyclophosphamide to 500 mg IV weekly.&#xD;
&#xD;
      Tolerance determined by the patient not reaching an escalation limiting toxicity AND patient&#xD;
      approval to dose escalate.&#xD;
&#xD;
      Patients then receive dexamethasone and isatuximab as maintenance treatment twice per month&#xD;
      for 12 months in the absence of disease progression or unacceptable toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 28, 2021</start_date>
  <completion_date type="Anticipated">September 21, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 21, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free proportion</measure>
    <time_frame>At 3 months</time_frame>
    <description>An event is defined as going off study due to toxicity, death or progression of disease. The events include off-study due to toxicity, death, or progression. The rate will be calculated with an exact 95% confidence interval using the efficacy evaluable population.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete hematologic response proportion</measure>
    <time_frame>Up to 19 months</time_frame>
    <description>Will be calculated with an exact 95% confidence interval.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>AL Amyloidosis</condition>
  <arm_group>
    <arm_group_label>Treatment (isatuximab, chemotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive Isatuximab plus dexamethasone 4 mg PO/IV days weekly. Based on tolerance, patients will add to their treatment subcutaneous Velcade (earliest time to add Velcade is cycle 1 day 15) and intravenous cyclophosphamide (earliest time to add cyclophosphamide is cycle 4 day 1)&#xD;
Patients then receive dexamethasone and isatuximab as maintenance treatment twice per month for 12 months in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (isatuximab, chemotherapy)</arm_group_label>
    <other_name>[(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid</other_name>
    <other_name>LDP 341</other_name>
    <other_name>MLN341</other_name>
    <other_name>PS-341</other_name>
    <other_name>PS341</other_name>
    <other_name>Velcade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Treatment (isatuximab, chemotherapy)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamide Monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Treatment (isatuximab, chemotherapy)</arm_group_label>
    <other_name>Aacidexam</other_name>
    <other_name>Adexone</other_name>
    <other_name>Aknichthol Dexa</other_name>
    <other_name>Alba-Dex</other_name>
    <other_name>Alin</other_name>
    <other_name>Alin Depot</other_name>
    <other_name>Alin Oftalmico</other_name>
    <other_name>Amplidermis</other_name>
    <other_name>Anemul mono</other_name>
    <other_name>Auricularum</other_name>
    <other_name>Auxiloson</other_name>
    <other_name>Baycadron</other_name>
    <other_name>Baycuten</other_name>
    <other_name>Baycuten N</other_name>
    <other_name>Cortidexason</other_name>
    <other_name>Cortisumman</other_name>
    <other_name>Decacort</other_name>
    <other_name>Decadrol</other_name>
    <other_name>Decadron</other_name>
    <other_name>Decadron DP</other_name>
    <other_name>Decalix</other_name>
    <other_name>Decameth</other_name>
    <other_name>Decasone R.p.</other_name>
    <other_name>Dectancyl</other_name>
    <other_name>Dekacort</other_name>
    <other_name>Deltafluorene</other_name>
    <other_name>Deronil</other_name>
    <other_name>Desamethasone</other_name>
    <other_name>Desameton</other_name>
    <other_name>Dexa-Mamallet</other_name>
    <other_name>Dexa-Rhinosan</other_name>
    <other_name>Dexa-Scheroson</other_name>
    <other_name>Dexa-sine</other_name>
    <other_name>Dexacortal</other_name>
    <other_name>Dexacortin</other_name>
    <other_name>Dexafarma</other_name>
    <other_name>Dexafluorene</other_name>
    <other_name>Dexalocal</other_name>
    <other_name>Dexamecortin</other_name>
    <other_name>Dexameth</other_name>
    <other_name>Dexamethasone Intensol</other_name>
    <other_name>Dexamethasonum</other_name>
    <other_name>Dexamonozon</other_name>
    <other_name>Dexapos</other_name>
    <other_name>Dexinoral</other_name>
    <other_name>Dexone</other_name>
    <other_name>Dinormon</other_name>
    <other_name>Fluorodelta</other_name>
    <other_name>Fortecortin</other_name>
    <other_name>Gammacorten</other_name>
    <other_name>Hexadecadrol</other_name>
    <other_name>Hexadrol</other_name>
    <other_name>Lokalison-F</other_name>
    <other_name>Loverine</other_name>
    <other_name>Methylfluorprednisolone</other_name>
    <other_name>Millicorten</other_name>
    <other_name>Mymethasone</other_name>
    <other_name>Orgadrone</other_name>
    <other_name>Spersadex</other_name>
    <other_name>TaperDex</other_name>
    <other_name>Visumetazone</other_name>
    <other_name>ZoDex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Isatuximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (isatuximab, chemotherapy)</arm_group_label>
    <other_name>Hu 38SB19</other_name>
    <other_name>Isatuximab-irfc</other_name>
    <other_name>SAR 650984</other_name>
    <other_name>SAR650984</other_name>
    <other_name>Sarclisa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histopathological diagnosis of amyloidosis based on detection by immunohistochemistry&#xD;
             (IHC) and polarizing light microscopy of green birefringent material in Congo&#xD;
             red-stained tissue specimens in an organ other than bone marrow, characteristic&#xD;
             electron microscopy appearance, or mass spectrometry. Specifically for male subjects&#xD;
             70 years of age or older who have cardiac involvement only and subjects of African&#xD;
             descent, mass spectrometry typing of AL amyloid in a tissue biopsy is recommended to&#xD;
             rule out other types of amyloidosis such as age-related amyloidosis or hereditary&#xD;
             amyloidosis (ATTR mutation)&#xD;
&#xD;
          -  Must have evidence of high risk AL amyloidosis defined as one of the following any&#xD;
             time within the 6 months prior to consent:&#xD;
&#xD;
               -  Biomarker-based indicators of severe disease: NT-proBNP &gt; 8500 ng/L OR hs-cTnT &gt;=&#xD;
                  50 ng/L&#xD;
&#xD;
               -  BUMC 2019 stage 3b requiring both TnI &gt; 0.1 ng/mL and BNP &gt; 700 pg/mL&#xD;
&#xD;
               -  Mayo 2012 stage 4 that includes each of the following a) cTnT &gt;= 0.025 ng/mL or&#xD;
                  hs-cTnT &gt;= 40 ng/mL; b) NT-proBNP &gt;= 1800 pg/mL; and c) dFLC &gt;= 180 mg/L&#xD;
&#xD;
               -  Significant AL amyloid related hypotension (systolic blood pressure [SBP] &lt; 100&#xD;
                  mm Hg or symptomatic orthostatic hypotension defined as a decrease in systolic&#xD;
                  blood pressure upon standing of &gt; 20 mm Hg despite medical management&#xD;
                  [fludrocortisone, midodrine, etc] in the absence of volume depletion)&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1000/uL&#xD;
&#xD;
          -  Platelet count &gt;= 50,000 and platelet transfusion independent for 1 week prior to&#xD;
             screening&#xD;
&#xD;
          -  Estimated creatinine clearance &gt;= 20 mL/min/1.73 m^2 as defined by Chronic Kidney&#xD;
             Disease Epidemiology Collaboration equation (CKD-EPI)&#xD;
&#xD;
          -  Total bilirubin &lt; 1.5 x institutional upper limit of normal (IULN) except for patients&#xD;
             with Gilbert syndrome in which case total bilirubin =&lt; 2 x IULN&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) &lt; 3 x IULN&#xD;
&#xD;
          -  Left ventricular ejection fraction &gt;= 30%&#xD;
&#xD;
          -  Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy&#xD;
             test with a sensitivity of at least 25 mIU/mL within 10 - 14 days prior to and again&#xD;
             within 24 hours of starting study medication. The effects of protocol therapy on the&#xD;
             developing human fetus are unknown. For this reason, FCBP and men must agree to use&#xD;
             adequate contraception (hormonal or barrier method of birth control; abstinence) prior&#xD;
             to study entry, for the duration of study participation, and for 5 months after&#xD;
             completion of protocol therapy. Men must refrain from donating sperm during the same&#xD;
             period that they must agree to use contraception. Should a woman become pregnant or&#xD;
             suspect she is pregnant while she or her partner is participating in this study, she&#xD;
             should inform her treating physician immediately. A female of childbearing potential&#xD;
             (FCBP) is a sexually mature woman who: 1) has not undergone a hysterectomy or&#xD;
             bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24&#xD;
             consecutive months (i.e., has had menses at any time in the preceding 24 consecutive&#xD;
             months&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
          -  Patients with a prior or concurrent malignancy whose natural history or treatment does&#xD;
             not have the potential to interfere with the safety or efficacy assessment of the&#xD;
             investigational regimen are eligible for this trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &gt; 1 prior line of therapy&#xD;
&#xD;
          -  Refractory to any proteasome inhibitor&#xD;
&#xD;
          -  Prior CD38 antibody exposure&#xD;
&#xD;
          -  Cardiac exclusions:&#xD;
&#xD;
               -  Subjects with a history of sustained ventricular tachycardia EXCEPT in patients&#xD;
                  with a pacemaker/implantable cardioverter defibrillator (ICD)&#xD;
&#xD;
               -  Baseline QT interval as corrected by institutional rate correction algorithm&#xD;
                  (e.g. corrected QT interval by Bazett formula [QTc]B or corrected QT interval by&#xD;
                  Fridericia formula [QTcF]) &gt; 500 msec EXCEPT in patients with a pacemaker&#xD;
&#xD;
          -  Grade 2 or greater peripheral sensory neuropathy&#xD;
&#xD;
          -  Received any investigational drug within 14 days or 5 half-lives of the&#xD;
             investigational drug, whichever is longer&#xD;
&#xD;
          -  Hypersensitivity or history of intolerance to steroids, mannitol, pregelatinized&#xD;
             starch, sodium stearyl fumarate, histidine (as base and hydrochloride salt), arginine&#xD;
             hydrochloride, poloxamer 188, sucrose or any of the other components of study therapy&#xD;
             that are not amenable to premedication with steroids and H2 blockers or would prohibit&#xD;
             further treatment with these agents&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV) positive EXCEPT if the patient meets all the&#xD;
             following: CD4 &gt; 350 cells/mm3, undetectable viral load, maintained on modern&#xD;
             therapeutic regimen utilizing non CYP interacting agents (e.g. excluding ritonavir),&#xD;
             and no untreated acquired immune deficiency syndrome defining opportunistic infections&#xD;
&#xD;
          -  Seropositive for hepatitis B surface antigen [HBsAg]) EXCEPT subjects with resolved&#xD;
             infection (i.e., subjects who are positive for antibodies to hepatitis B core antigen&#xD;
             [antiHBc] and/or antibodies to hepatitis B surface antigen [antiHBs]) must be screened&#xD;
             using real-time polymerase chain reaction (PCR) measurement of hepatitis B virus (HBV)&#xD;
             deoxyribonucleic acid (DNA) levels. Those who are PCR positive will be excluded.&#xD;
             Subjects with serologic findings suggestive of HBV vaccination (antiHBs positivity as&#xD;
             the only serologic marker) AND a known history of prior HBV vaccination, do not need&#xD;
             to be tested for HBV DNA by PCR&#xD;
&#xD;
          -  Seropositive for hepatitis C EXCEPT in the setting of a sustained virologic response&#xD;
             [SVR], defined as without viremia for at least 12 weeks after completion of antiviral&#xD;
             therapy&#xD;
&#xD;
          -  Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes&#xD;
             (POEMS) syndrome, wild type or mutated (ATTR) amyloidosis, and Waldenstrom&#xD;
             macroglobulinemia&#xD;
&#xD;
          -  Known allergies, hypersensitivity, or intolerance to monoclonal antibodies,&#xD;
             hyaluronidase, human proteins, or their excipients (refer to investigational brochure&#xD;
             [IB]), or known sensitivity to mammalian-derived products&#xD;
&#xD;
          -  Patients who have had any plasma cell directed treatment, radiotherapy,&#xD;
             plasmapheresis, or major surgery (as defined by the investigator) within 1 week prior&#xD;
             to cycle 1 day 1 of the study. Patients may be receiving concomitant therapy with low&#xD;
             dose corticosteroids (e.g., prednisone up to but no more than 10 mg by mouth daily or&#xD;
             its equivalent) for symptom management and comorbid conditions&#xD;
&#xD;
          -  Concurrent medical condition or disease (e.g., active infection requiring treatment&#xD;
             with a parenteral antibiotic, active tuberculosis, etc) that would expose excessive&#xD;
             risk to the patient or may interfere with compliance or interpretation of the study&#xD;
             results&#xD;
&#xD;
          -  Known or suspected of not being able to comply with the study protocol (e.g.&#xD;
             alcoholism, drug dependency, or psychological disorder) or the subject has any&#xD;
             condition for which, in the opinion of the investigator, participation would not be in&#xD;
             the best interest of the subject (e.g., compromise their well-being) or that could&#xD;
             prevent, limit, or confound the protocol-specified assessments&#xD;
&#xD;
          -  Pregnant women are excluded from this study because protocol therapy has the potential&#xD;
             for teratogenic or abortifacient effects. Because there is an unknown but potential&#xD;
             risk for adverse events in nursing infants secondary to protocol treatment of the&#xD;
             mother, breastfeeding should be discontinued. Women planning to become pregnant 1 year&#xD;
             after discontinuation of cyclophosphamide or 3 months following discontinuation of&#xD;
             isatuximab&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig C Hofmeister, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Craig C Hofmeister, MD, MPH</last_name>
    <phone>404-778-1900</phone>
    <email>craig.hofmeister@emory.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Sandy Wong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital/Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shondolyn C. Richburg</last_name>
      <phone>404-778-3612</phone>
      <email>shondolyn.k.richburg@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Craig C. Hofmeister</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital Midtown</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>39322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shondolyn Richburg</last_name>
      <phone>404-778-3612</phone>
      <email>shondolyn.richburg@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jeffrey Zonder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Suzanne Lentzsch, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ankit Kasangra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 9, 2021</study_first_submitted>
  <study_first_submitted_qc>February 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2021</study_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Craig Hofmeister</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulin Light-chain Amyloidosis</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Ichthammol</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

